Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00279721
Recruitment Status : Completed
First Posted : January 20, 2006
Last Update Posted : January 19, 2012
Sponsor:
Information provided by:
AHS Cancer Control Alberta

Brief Summary:
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Condition or disease Intervention/treatment Phase
Thyroid Neoplasms Procedure: IMRT Phase 2

Detailed Description:
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.
Study Start Date : January 2006
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid




Primary Outcome Measures :
  1. toxicity according to RTOG criteria
  2. locoregional control


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion Criteria:

  • medullary or anaplastic thyroid cancer, unresectable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00279721


Sponsors and Collaborators
Alberta Health Services
Investigators
Layout table for investigator information
Principal Investigator: Harold Lau, MD Tom Baker Cancer Centre
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00279721    
Other Study ID Numbers: 18916
First Posted: January 20, 2006    Key Record Dates
Last Update Posted: January 19, 2012
Last Verified: July 2011
Keywords provided by AHS Cancer Control Alberta:
thyroid neoplasms
intensity modulated radiation
radiotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms